Early access
Sign in
Active, not recruitingPhase 3

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Key facts

Who runs it
Definium Therapeutics US, Inc.
Where
Atlanta, Austin, Boston, Bradenton, Cincinnati, Everett, Little Rock, Los Angeles, North Canton, Orlando, Princeton, and Towson, United StatesSee the 13 sitesAlso in 5 other countries, 22 sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
245 people enrolled
Started
29 Jan 2025
Expected to end
May 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Placebo
  • DT120
Record updated
4 September 2026

Who can take part

Age
18 years to 74 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Diagnosis of GAD per DSM-5
  • Male or female aged 18 to 74
  • HAM-A Total Score ≥20

Who cannot take part

  • Certain psychiatric disorders (other than generalized anxiety disorder)
  • First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
  • Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
  • Any clinically significant unstable illness

Where in United States

Also in 5 other countries, 22 sites

  • Atlanta Center for Medical ResearchAtlanta, United States
  • Austin Clinical Trial PartnersAustin, United States
  • Adams Clinical BostonBoston, United States
  • Bradenton Research Center, Inc.Bradenton, United States
  • University of Cincinnati Psychiatry- Anxiety Disorders Research ProgramCincinnati, United States
  • Core Clinical ResearchEverett, United States
  • Preferred Research Partners, IncLittle Rock, United States
  • Psychedelic Science InstituteLos Angeles, United States
  • West Los Angeles VA Medical CenterLos Angeles, United States
  • Neuro-Behavioral Clinical Research Inc.North Canton, United States
  • Clinical Neuroscience Solutions, Inc.Orlando, United States
  • Princeton Medical InstitutePrinceton, United States
  • Sheppard Pratt Health SystemTowson, United States

About the trial

What the trial wants to find out

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Panorama

The 3 groups in the trial

  • Arm 1 - PlaceboPlacebo, for comparison

    A substance that is designed to have no therapeutic value

    Treatment: Placebo

  • Arm 2 - 50µg DT120Sham treatment, for comparison

    A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

    Treatment: DT120

  • Arm 3 - 100µg DT120Treatment being tested

    A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

    Treatment: DT120

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama
Publications
Record updated
4 September 2026